The proteomics of drusen

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2014, Pages

  Crabb, John W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PATTERN RECOGNITION RECEPTOR; PROTEIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BIOGENESIS; BRUCH MEMBRANE; DISEASE COURSE; DRUSEN; ENVIRONMENTAL FACTOR; HUMAN; NONHUMAN; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE STUDY; ANIMAL; CHEMISTRY; CHOROID; DISEASE MODEL; GENETICS; IMMUNOLOGY; MACULAR DEGENERATION; METABOLISM; MOUSE; OXIDATIVE STRESS; PHYSIOLOGY;

ANIMALS; BRUCH MEMBRANE; CHOROID; DISEASE MODELS, ANIMAL; HUMANS; MACULAR DEGENERATION; MICE; OXIDATIVE STRESS; PROTEINS; PROTEOMICS; RETINAL DRUSEN;

EID: 84923829587     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017194     Document Type: Article

References (123)

1. Abdelsalam A, Del Priore L, Zarbin MA. 1999. Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 44: 1-29.
2. Age Related Eye Disease Study Group. 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, b carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
3. Allikmets R. 2000. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. Am J Hum Genet 67: 487-491.
4. Alvarez R, Aguirre G, Acland G, Anderson R. 1994. Doco-sapentaenoic acid is converted to docosahexaenoic acid in the retinas of normal and prcd-affected miniature poodle dogs. Invest Ophthalmol Vis Sci 35: 402-408.
5. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. 2004. Characterization of b amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration. Exp Eye Res 78: 243-256.
6. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, et al. 2010. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res 29: 95-112.
7. Baird PN, Richardson AJ, Robman LD, Dimitrov PN, Tikel-lis G, McCarty CA, Guymer RH. 2006. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat 27: 337-342.
8. Baynes JW. 2001. The role of AGEs in aging: Causation or correlation. Exp Gerontol 36: 1527-1537.
9. Beatty S, Koh H, Phil M, Henson D, Boulton M. 2000. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115-134.
10. Bok D. 2002. New insights and new approaches toward the study of age-related macular degeneration. Proc Natl Acad Sci 99: 14619-14621.
11. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. 2010. The dynamic nature of Bruch's membrane. Prog Retin Eye Res 29: 1-18.
12. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. 2007. RAGE: A potential target for Ab-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7: 735-742.
13. Chio KS, Reiss U, Fletcher B, Tappel AL. 1969. Peroxidation of subcellular organelles: Formation of lipofuscinlike fluorescent pigments. Science 166: 1535-1536.
14. Crabb JW. 2012. Oxidative modifications as triggers of AMD pathology. In Studies on Retinal and Choroidal Disorders (ed. Stratton R, Hauswirth W, Gardiner T), pp. 65-84. Humana Press.
15. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, et al. 2002a. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci 99: 14682-14687.
16. Crabb JW, O'Neil J, Miyagi M, West K, Hoff HF. 2002b. Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci 11:831-840.
17. Curcio CA, Millican CL. 1999. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol 117: 329-339.
18. Curcio CA, Presley JB, Malek G, Medeiros NE, Avery DV, Kruth HS. 2005a. Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy. Exp Eye Res 81: 731-741.
19. Curcio CA, Presley JB, Millican CL, Medeiros NE. 2005b. Basal deposits and drusen in eyes with age-related mac ulopathy: Evidence for solid lipid particles. Exp Eye Res 80: 761-775.
20. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. 2003. Amyloid-b is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9: 184-190.
21. Dewan A, Liu M, Hartman S, Zhang S, Liu D, Zhao C, Tam P, Chan W, Lam D, Snyder M, et al. 2006. HTRA1promoter polymorphism in wet age-related macular degeneration. Science 314: 989-992.
22. Ding X, Patel M, Chan CC. 2009. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28: 1-18.
23. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, et al. 2011. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci 108: E279-E287.
24. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. 2008. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: Anti-amyloid-b antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 48: 339-345.
25. Ebrahem Q, Renganathan K, Sears J, Vasanji A, Gu X, Lu L, Salomon RG, Crabb JW, Anand-Apte B. 2006. Carbox yethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sci 103: 13480-13484.
26. Edwards A, Ritter R, Abel K, Manning A, Panhuysen C, Farrer L. 2005. Complement factor H polymorphism and age-related macular degeneration. Science 308:421-424.
27. Eldred GE, Lasky MR. 1993. Retinal age pigments generated by self-assembling lysosomotropic detergents. Nature 361: 724-726.
28. Elgawish A, Glomb M, Friedlander M, Monnier VM. 1996. Involvement ofhydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. J Biol Chem 271:12964-12971.
29. Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128.
30. Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland LM, Handa JT. 1999. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization ofthese epitopes in Bruch's membrane of the aging eye. Mol Vis 5: 11.
31. Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, et al. 2004. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 18: 203-205.
32. Ferris FL III, Fine SL, Hyman L. 1984. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642.
33. Fliesler SJ, Anderson RE. 1983. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22: 79-131.
34. Friguet B, Stadtman ER, Szweda LI. 1994. Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J Biol Chem 269: 21639-21643.
35. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, et al. 2013. Seven new loci associated with age-related macular degeneration. Nat Genet 45: 433-439.
36. Fu L, Garland D, Yang Z, Shukla D, Rajendran A, Pearson E, Stone EM, Zhang K, Pierce EA. 2007. The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet 16: 2411-2422.
37. Garland DL, Fernandez-Godino R, Kaur I, Speicher KD, Harnly JM, Lambris JD, Speicher DW, Pierce EA. 2013. Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Hum Mol Genet 23:52-68.
38. Glenn JV, Beattie JR, Barrett L, Frizzell N, Thorpe SR, Boul-ton ME, McGarvey JJ, Stitt AW. 2007. Confocal Raman microscopycan quantifyadvanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FA-SEB J 21: 3542-3552.
39. Glenn JV, Mahaffy H, Wu K, Smith G, Nagai R, Simpson DA, Boulton ME, Stitt AW. 2009. Advanced glycation end product (AGE) accumulation on Bruch's membrane: Links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci 50: 441-451.
40. Goh SY, Cooper ME. 2008. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143-1152.
41. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, et al. 2006. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38: 458-462.
42. Goldberg MF. 1976. Bruch's membrane and vascular gowth. Invest Ophthalmol Vis Sci 15: 443-446.
43. Green WR, Enger C. 1993. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100: 1519-1535.
44. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, Salomon RG. 2003a. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 278: 42027-42035.
45. Gu X, Sun M, Gugiu B, Hazen S, Crabb JW, Salomon RG. 2003b. Oxidatively truncated docosahexaenoate phos-pholipids: Total synthesis, generation, and peptide adduction chemistry. J Org Chem 68: 3749-3761.
46. Gu J, Paeur GJ, Yue X, Narendra U, Sturgill GM, Bena J, Gu X, Peachey NS, Salomon RG, Hagstrom SA, et al. 2009. Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Molecular & Cellular Proteomics 8: 1338-1349.
47. Hageman G, Mullins R, Russell S, Johnson L, Anderson D. 1999. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J13: 477-484.
48. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, et al. 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH)pre-disposes individuals to age-related macular degeneration. Proc Natl Acad Sci 102: 7227-7232.
49. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. 2001. An integrated hypothesis that considers drusen as biomarkers ofimmune-me-diated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. ProgRetin Eye Res 20: 705-732.
50. Hagenow K, Gelderman KA, Hultqvist M, Merky P, Backlund J, Frey O, Kamradt T, Holmdahl R. 2009. Ncf1-as-sociated reduced oxidative burst promotes IL-33R+ T cell-mediated adjuvant-free arthritis in mice. JImmunol 183: 874-881.
51. Haines J, Hauser M, Schmidt S, Scott W, Olson L, Gallins P, Spencer K, Kwan S, Noureddine M, Gilbert J, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
52. Hammes HP, Hoerauf H, Alt A, Schleicher E, Clausen JT, Bretzel RG, Laqua H. 1999. N(s)(Carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 40:1855-1859.
53. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, Miyata T, Hjelmeland LM. 1999. Increase in the advanced glycation end product pentosi-dine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 40: 775-779.
54. Hazen SL. 2008. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem 283: 15527-15531.
55. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM. 2007. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 82: 204-212.
56. Hirata C, Nakano K, Nakamura N, Kitagawa Y, Shigeta H, Hasegawa G, Ogata M, Ikeda T, Sawa H, Nakamura K, et al. 1997. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun 236: 712-715.
57. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiede-mann P. 2002. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metallo-proteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 240: 996-1002.
58. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG, Perez VL. 2008. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 14: 194-198.
59. Howes KA, Liu Y, Dunaief JL, Milam A, Frederick JM, Marks A, Baehr W. 2004. Receptor for advanced glycation end products and age-related macular degeneration. Invest Ophthalmol Vis Sci 45: 3713-3720.
60. Isas JM, Luibl V, Johnson LV, Kayed R, Wetzel R, Glabe CG, Langen R, Chen J. 2010. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 51:1304-1310.
61. Ishibashi T, Murata T, Hangai M, Nagai R, Horiuchi S, Lopez PF, Hinton DR, Ryan SJ. 1998. Advanced glycation end products in age-related macular degeneration. Arch Oph-thalmol 116: 1629-1632.
62. Jager R, Mieler W, Miller J. 2008. Age-related macular degeneration. NEngl J Med 358: 2606-2617.
63. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. 1994. b-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. JImmunol 152: 5050-5059.
64. Jiang K, To E, Cui JZ, Cao SJG, Matsubara JA. 2012. Drusen and pro-inflammatory mediators in the post-mortem human eye. J Clinic Experiment Ophthalmol 3: 208-216.
65. Johnson LV. 2002. The Alzheimer's Ab-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci 99: 11830-11835.
66. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. 2000. A potential role for immune complex patho-genesis in drusen formation. Exp Eye Res 70: 441-449.
67. Johnson LV, Forest DL, Banna CD, Radeke CM, Maloney MA, Hu J, Spencer CN, Walker AM, Tsie MS, Bok D, et al. 2011. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci 108: 18277-18282.
68. Kamei M, Hollyfield JG. 1999. TIMP-3 in Bruch's membrane: Changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 40: 2367-2375.
69. Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, He S, Lyons R, Abecasis GR, Swaroop A. 2007. A variant of mitochondrial protein LOC387715/ ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci 104:16227-16232.
70. Kim SR, Jang YP, Jockusch S, Fishkin NE, Turro NJ, Sparrow JR. 2007. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proc Natl Acad Sci 104: 19273-19278.
71. Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C, Hen-ning A, SanGiovanni J, Mane S, Mayne S, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
72. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. 2008. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9: 505-518.
73. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. 2005. LPS receptor (CD14): A receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 128: 1778-1789.
74. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, Devera ME, Liang X, Tor M, Billiar T. 2007. The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220: 60-81.
75. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. 1998. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101: 1219-1224.
76. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. 2006. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. JClin Invest 116: 378-385.
77. Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA. 2003. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am JPathol 162: 413-425.
78. Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, Toth CA, Sullivan PM, Bowes Rickman C. 2005. Apolipoprotein E allele-dependent pathogenesis: A model for age-related retinal degeneration. Proc Natl Acad Sci 102: 11900-11905.
79. Marmorstein LY. 2002. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc Natl Acad Sci 99:13067-13072.
80. Marmorstein LY, McLaughlin PJ, Peachey NS, Sasaki T, Mar-morstein AD. 2007. Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: A model for the early pathogenic course of macular degeneration. Hum Mol Genet 16: 2423-2432.
81. Matsue H, Edelbaum D, Shalhevet D, Mizumoto N, Yang C, Mummert ME, Oeda J, Masayasu H, Takashima A. 2003. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 171: 3010-3018.
82. Michaelides M, Jenkins SA, Brantley MA Jr, Andrews RM, Waseem N, Luong V, Gregory-Evans K, Bhattacharya SS, Fitzke FW, Webster AR. 2006. Maculopathy due to the R345W substitution in fibulin-3: Distinct clinical features, disease variability, and extent of retinal dysfunction. Invest Ophthalmol Vis Sci 47: 3085-3097.
83. Mullins R, Russell S, Anderson D, Hageman G. 2000. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14: 835-846.
84. Ng KP, Gugiu B, Renganathan K, Davies MW, Gu X, Crabb JS, Kim SR, Rozanowska MB, Bonilha VL, Rayborn ME, et al. 2008. Retinal pigment epithelium lipofuscin prote-omics. Mol Cell Proteomics 7: 1397-1405.
85. Ni J, Yuan X, Gu J, Yue X, Gu X, Nagaraj RH, Crabb JW, Group. TCGaPAS. 2009. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics 8: 1921-1933.
86. Nordgaard CL, Karunadharma PP, Feng X, Olsen TW, Ferrington DA. 2008. Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 2848-2855.
87. Okamoto T, Tanaka S, Stan AC, Koike T, Kase M, Makita Z, Sawa H, Nagashima K. 2002. Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 63:186-195.
88. Panigrahi S, Ma Y, Hong L, Gao D, West XZ, Salomon RG, Byzova TV, Podrez EA. 2013. Engagement ofplatelet tolllike receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res 112:103-112.
89. Penfold PL, Madigan MC, Gillies MC, Provis JM. 2001. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20: 385-414.
90. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. 2005. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14:3227-3236.
91. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. 1992. Complement activation by b-amyloid in Alzheimer disease. Proc Natl Acad Sci 89: 10016-10020.
92. Sakaguchi H, Miyagi M, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG. 2002. Clusterin is present in drusen in age-related macular degeneration. Exp Eye Res 74: 547-549.
93. Sakai N, Decatur J, Nakanishi K, Eldred GE. 1996. Ocular age pigment "A2-E": An unprecedented pyridinium bis-retinoid. J Am Chem Soc 118: 1559-1560.
94. Sarks S. 1976. Aging and degeneration in the macular region: A clinico-pathological study. Br J Ophthalmol 60:324-328.
95. Sarks S, Cherepanoff S, Killingsworth M, Sarks J. 2007. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 48:968-977.
96. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. 2009. The role of RAGE in amyloid-b peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 10: 672-680.
97. Schutt F, Bergmann M, Holz FG, Kopitz J. 2003. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci 44: 3663-3668.
98. Seddon JM, Willett WC, Speizer FE, Hankinson SE. 1996. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276: 1141-1146.
99. Shaw PX, Zhang L, Zhang M, Du H, Zhao L, Lee C, Grob S, Lim SL, Hughes G, Lee J, et al. 2012. Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci 109: 13757-13762.
100. Shen JK, Dong A, Hackett SF, Bell WR, Green WR, Campochiaro PA. 2007. Oxidative damage in age-related macular degeneration. Histol Histopathol 22: 1301-1308.
101. Sparrow JR. 2007. RPE lipofuscin: formation, properties, and relevance to retinal degeneration. In Retinal Degenerations: Biology, Diagnostics and Therapeutics (ed. Tom-bran-Tink J, Barnstable CJ), pp. 213-236. Human Press, Totowa, NJ.
102. Sparrow JR, Boulton M. 2005. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 80: 595-606.
103. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ, et al. 2009. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. JTranslMed 7: 17.
104. Spraul C, Grossniklaus H. 1997. Characteristics of dru-sen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Ophthalmology 115:267-273.
105. Stone EM, Lotery AJ, Munier FL, Heon E, Piguet B, Guymer RH, Vandenburgh K, Cousin P, Nishimura D, Swiderski RE, et al. 1999. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 22: 199-202.
106. Stone EM, Braun TA, Russell SR, Kuehn MH, Lotery AJ, Moore PA, Eastman CG, Casavant TL, Sheffield VC. 2004. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med 351: 346-353.
107. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. 2001. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276: 43836-43841.
108. Umeda S, Suzuki M, Okamoto H, Ono F, Mizota A, Terao K, Yoshikawa Y, Tanaka Y, Iwata T. 2005. Molecular composition ofdrusen and possible involvement ofanti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J 19: 1683-1685.
109. Urata Y, Yamaguchi M, Higashiyama Y, Ihara Y, Goto S, Kuwano M, Horiuchi S, Sumikawa K, Kondo T. 2002. Reactive oxygen species accelerate production ofvascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic Biol Med 32: 688-701.
110. Verhasselt V, Goldman M, Willems F. 1998. Oxidative stress up-regulates IL-8 and TNF-a synthesis by human dendritic cells. Eur J Immunol 28: 3886-3890.
111. Wang N, Anderson RE. 1992. Enrichment ofpolyunsaturat-ed fatty acids from rat retinal pigment epithelium to rod outer segments. Curr Eye Res 11: 783-791.
112. Wang L, Clark M, Crossman D, Kojima K, Messinger J, Mobley J, Curcio C. 2010. Abundant lipid and protein components of drusen. PLoS ONE 5: e10329.
113. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P, Cano M, Brandstatter H, Tsimikas S, Skerka C, et al. 2011. Complement factor H binds ma-londialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.
114. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Podrez EA, Salomon RG, Byzova TV. 2010. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467: 972-976.
115. Wu Y, Yanase E, Feng X, Siegel MM, Sparrow JR. 2010. Structural characterization of bisretinoid A2E photo-cleavage products and implications for age-related macular degeneration. Proc Natl Acad Sci 107: 7275-7280.
116. Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ, Chen H, Zhao Y, Pearson E, Li X, et al. 2006. Avariant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314: 992-993.
117. Yates J, Sepp T, Matharu B, Khan J, Thurlby D, Shahid H, Clayton D, Hayward C, Morgan J, Wright A, et al. 2007. Complement C3 variant and the risk of age-related macular degeneration. NEngl J Med 357: 553-561.
118. Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I. 2005. The potential role of amyloid b in the pathogenesis of age-related macular degeneration. J Clin Invest 115:2793-2800.
119. Yuan X, Gu X, Crabb JS, Yue X, Shadrach K, Hollyfield JG, Crabb JW. 2010. Quantitative proteomics: Comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics 9: 1031-1046.
120. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. 2008. TLR2—promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213: 205-224.
121. Zarbin MA. 2004. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598-614.
122. Zareparsi S, Reddick AC, Branham KE, Moore KB, Jessup L, Thoms S, Smith-Wheelock M, Yashar BM, Swaroop A. 2004. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. Invest Ophthalmol Vis Sci 45: 1306-1310.
123. Zareparsi S, Buraczynska M, Branham KE, Shah S, Eng D, Li M, Pawar H, Yashar BM, Moroi SE, Lichter PR, et al. 2005. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum Mol Genet 14: 1449-1455.